Search

David J. Parsley

Examiner (ID: 15367, Phone: (571)272-6890 , Office: P/3643 )

Most Active Art Unit
3643
Art Unit(s)
3643
Total Applications
2041
Issued Applications
924
Pending Applications
184
Abandoned Applications
965

Applications

Application numberTitle of the applicationFiling DateStatus
Array ( [id] => 19201379 [patent_doc_number] => 20240173278 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-05-30 [patent_title] => SYSTEMS AND METHODS FOR SUPPLYING NUTRITIONAL SUPPLEMENTS THAT ELIMINATE PERVASIVE ODORS [patent_app_type] => utility [patent_app_number] => 18/059142 [patent_app_country] => US [patent_app_date] => 2022-11-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 4696 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 40 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18059142 [rel_patent_id] =>[rel_patent_doc_number] =>)
18/059142
SYSTEMS AND METHODS FOR SUPPLYING NUTRITIONAL SUPPLEMENTS THAT ELIMINATE PERVASIVE ODORS Nov 27, 2022 Pending
Array ( [id] => 18360453 [patent_doc_number] => 20230142044 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-05-11 [patent_title] => METHOD OF PROVIDING CELIPROLOL THERAPY TO A PATIENT [patent_app_type] => utility [patent_app_number] => 17/985627 [patent_app_country] => US [patent_app_date] => 2022-11-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 13223 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -6 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17985627 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/985627
METHOD OF PROVIDING CELIPROLOL THERAPY TO A PATIENT Nov 10, 2022 Abandoned
Array ( [id] => 18312620 [patent_doc_number] => 20230116520 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-04-13 [patent_title] => CO-CRYSTALS [patent_app_type] => utility [patent_app_number] => 17/973297 [patent_app_country] => US [patent_app_date] => 2022-10-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 34137 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 68 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17973297 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/973297
Co-crystals Oct 24, 2022 Issued
Array ( [id] => 18107907 [patent_doc_number] => 20230000787 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-01-05 [patent_title] => Zeaxanthin Formulations With Additional Ocular-Active Nutrients, For Protecting Eye Health And Treating Eye Disorders [patent_app_type] => utility [patent_app_number] => 17/930709 [patent_app_country] => US [patent_app_date] => 2022-09-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 20163 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17930709 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/930709
Zeaxanthin Formulations With Additional Ocular-Active Nutrients, For Protecting Eye Health And Treating Eye Disorders Sep 7, 2022 Abandoned
Array ( [id] => 18284986 [patent_doc_number] => 20230100458 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-03-30 [patent_title] => NOVEL ANTHRANILIC AMIDES AND THE USE THEREOF [patent_app_type] => utility [patent_app_number] => 17/897116 [patent_app_country] => US [patent_app_date] => 2022-08-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 16801 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17897116 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/897116
NOVEL ANTHRANILIC AMIDES AND THE USE THEREOF Aug 25, 2022 Abandoned
Array ( [id] => 19032462 [patent_doc_number] => 20240082277 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-03-14 [patent_title] => MODIFIED ANTIHISTAMINE COMPOSITION AND ANTIVIRAL TREATMENT [patent_app_type] => utility [patent_app_number] => 17/890816 [patent_app_country] => US [patent_app_date] => 2022-08-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 3358 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -9 [patent_words_short_claim] => 5 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17890816 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/890816
MODIFIED ANTIHISTAMINE COMPOSITION AND ANTIVIRAL TREATMENT Aug 17, 2022 Abandoned
Array ( [id] => 20171707 [patent_doc_number] => 12390427 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-08-19 [patent_title] => Plasminogen activator inhibitor-1 (PAI-1) inhibitor and method of use [patent_app_type] => utility [patent_app_number] => 17/883245 [patent_app_country] => US [patent_app_date] => 2022-08-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 9 [patent_figures_cnt] => 21 [patent_no_of_words] => 4685 [patent_no_of_claims] => 4 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 24 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17883245 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/883245
Plasminogen activator inhibitor-1 (PAI-1) inhibitor and method of use Aug 7, 2022 Issued
Array ( [id] => 19104611 [patent_doc_number] => 11957684 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-04-16 [patent_title] => Treatment of heavy menstrual bleeding associated with uterine fibroids [patent_app_type] => utility [patent_app_number] => 17/866201 [patent_app_country] => US [patent_app_date] => 2022-07-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 224 [patent_figures_cnt] => 262 [patent_no_of_words] => 112490 [patent_no_of_claims] => 22 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 67 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17866201 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/866201
Treatment of heavy menstrual bleeding associated with uterine fibroids Jul 14, 2022 Issued
Array ( [id] => 19104611 [patent_doc_number] => 11957684 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-04-16 [patent_title] => Treatment of heavy menstrual bleeding associated with uterine fibroids [patent_app_type] => utility [patent_app_number] => 17/866201 [patent_app_country] => US [patent_app_date] => 2022-07-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 224 [patent_figures_cnt] => 262 [patent_no_of_words] => 112490 [patent_no_of_claims] => 22 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 67 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17866201 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/866201
Treatment of heavy menstrual bleeding associated with uterine fibroids Jul 14, 2022 Issued
Array ( [id] => 19104611 [patent_doc_number] => 11957684 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-04-16 [patent_title] => Treatment of heavy menstrual bleeding associated with uterine fibroids [patent_app_type] => utility [patent_app_number] => 17/866201 [patent_app_country] => US [patent_app_date] => 2022-07-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 224 [patent_figures_cnt] => 262 [patent_no_of_words] => 112490 [patent_no_of_claims] => 22 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 67 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17866201 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/866201
Treatment of heavy menstrual bleeding associated with uterine fibroids Jul 14, 2022 Issued
Array ( [id] => 19104611 [patent_doc_number] => 11957684 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-04-16 [patent_title] => Treatment of heavy menstrual bleeding associated with uterine fibroids [patent_app_type] => utility [patent_app_number] => 17/866201 [patent_app_country] => US [patent_app_date] => 2022-07-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 224 [patent_figures_cnt] => 262 [patent_no_of_words] => 112490 [patent_no_of_claims] => 22 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 67 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17866201 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/866201
Treatment of heavy menstrual bleeding associated with uterine fibroids Jul 14, 2022 Issued
Array ( [id] => 19497570 [patent_doc_number] => 20240336588 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-10-10 [patent_title] => COMPOSITIONS AND METHODS FOR ANTIOXIDANT AND ANTI-INFLAMMATORY THERAPEUTICS [patent_app_type] => utility [patent_app_number] => 18/576176 [patent_app_country] => US [patent_app_date] => 2022-07-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 51985 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -22 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18576176 [rel_patent_id] =>[rel_patent_doc_number] =>)
18/576176
COMPOSITIONS AND METHODS FOR ANTIOXIDANT AND ANTI-INFLAMMATORY THERAPEUTICS Jul 13, 2022 Pending
Array ( [id] => 19360783 [patent_doc_number] => 20240262817 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-08-08 [patent_title] => QUINAZOLINE DERIVATIVES TARGETING R(CCUG) REPEATS IN MYOTONIC DYSTROPHY TYPE 2 [patent_app_type] => utility [patent_app_number] => 18/560558 [patent_app_country] => US [patent_app_date] => 2022-07-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 18573 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -41 [patent_words_short_claim] => 63 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18560558 [rel_patent_id] =>[rel_patent_doc_number] =>)
18/560558
QUINAZOLINE DERIVATIVES TARGETING R(CCUG) REPEATS IN MYOTONIC DYSTROPHY TYPE 2 Jul 12, 2022 Pending
Array ( [id] => 18003431 [patent_doc_number] => 20220362197 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-11-17 [patent_title] => LIPIDS WITH ODD NUMBER OF CARBON ATOMS AND THEIR USE AS PHARMACEUTICAL COMPOSITION OR NUTRITIONAL SUPPLEMENT [patent_app_type] => utility [patent_app_number] => 17/810044 [patent_app_country] => US [patent_app_date] => 2022-06-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 23047 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -4 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17810044 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/810044
LIPIDS WITH ODD NUMBER OF CARBON ATOMS AND THEIR USE AS PHARMACEUTICAL COMPOSITION OR NUTRITIONAL SUPPLEMENT Jun 29, 2022 Pending
Array ( [id] => 17944288 [patent_doc_number] => 20220331305 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-10-20 [patent_title] => Pharmaceutical Compositions Comprising Alpelisib [patent_app_type] => utility [patent_app_number] => 17/853537 [patent_app_country] => US [patent_app_date] => 2022-06-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 11407 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -28 [patent_words_short_claim] => 135 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17853537 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/853537
Pharmaceutical Compositions Comprising Alpelisib Jun 28, 2022 Pending
Array ( [id] => 17928333 [patent_doc_number] => 20220323458 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-10-13 [patent_title] => SUSTAINED RELEASE OLANZAPINE FORMULATIONS [patent_app_type] => utility [patent_app_number] => 17/847685 [patent_app_country] => US [patent_app_date] => 2022-06-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 8598 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 139 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17847685 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/847685
SUSTAINED RELEASE OLANZAPINE FORMULATIONS Jun 22, 2022 Abandoned
Array ( [id] => 19667418 [patent_doc_number] => 12180145 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-12-31 [patent_title] => Fused cyclooctyne compounds and their use in metal-free click reactions [patent_app_type] => utility [patent_app_number] => 17/839202 [patent_app_country] => US [patent_app_date] => 2022-06-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 6 [patent_figures_cnt] => 7 [patent_no_of_words] => 11584 [patent_no_of_claims] => 27 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 645 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17839202 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/839202
Fused cyclooctyne compounds and their use in metal-free click reactions Jun 12, 2022 Issued
Array ( [id] => 19343494 [patent_doc_number] => 20240252457 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-08-01 [patent_title] => Treatment or Prevention of Ischaemia Reperfusion Injury [patent_app_type] => utility [patent_app_number] => 18/568243 [patent_app_country] => US [patent_app_date] => 2022-06-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 12054 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -24 [patent_words_short_claim] => 96 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18568243 [rel_patent_id] =>[rel_patent_doc_number] =>)
18/568243
Treatment or Prevention of Ischaemia Reperfusion Injury Jun 7, 2022 Pending
Array ( [id] => 19402112 [patent_doc_number] => 20240285623 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-08-29 [patent_title] => TRPA1 CHANNEL ANTAGONIST COMPOUND FOR USE IN DEGENERATIVE RETINAL DISEASES [patent_app_type] => utility [patent_app_number] => 18/567877 [patent_app_country] => US [patent_app_date] => 2022-06-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 8973 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18567877 [rel_patent_id] =>[rel_patent_doc_number] =>)
18/567877
TRPA1 CHANNEL ANTAGONIST COMPOUND FOR USE IN DEGENERATIVE RETINAL DISEASES Jun 6, 2022 Pending
Array ( [id] => 19387800 [patent_doc_number] => 20240277670 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-08-22 [patent_title] => SAFE USE OF MMP-12 INHIBITOR [patent_app_type] => utility [patent_app_number] => 18/568043 [patent_app_country] => US [patent_app_date] => 2022-06-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 12805 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -29 [patent_words_short_claim] => 75 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18568043 [rel_patent_id] =>[rel_patent_doc_number] =>)
18/568043
SAFE USE OF MMP-12 INHIBITOR Jun 6, 2022 Pending
Menu